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The interferon-induced host restriction factor teth-
erin poses a barrier for SIV transmission from
primates to humans. After cross-species transmis-
sion, the chimpanzee precursor of pandemic HIV-1
switched from the accessory protein Nef to Vpu to
effectively counteract human tetherin. As we report
here, the experimental reintroduction of HIV-1 into
its original chimpanzee host resulted in a virus that
can use both Vpu and Nef to antagonize chimpanzee
tetherin. Functional analyses demonstrated that
alterations in and near the highly conserved ExxxLL
motif in the C-terminal loop of Nef were critical for
the reacquisition of antitetherin activity. Strikingly,
just two amino acid changes allowed HIV-1 Nef to
counteract chimpanzee tetherin and promote virus
release. Our data demonstrate that primate lentivi-
ruses can reacquire lost accessory gene functions
during a single in vivo passage and suggest that
other functional constraints keep Nef ready to regain
antitetherin activity.
INTRODUCTION
As a consequence of retroviral threat over millions of years, hu-
mans have evolved antiviral factors that act at different stages of
the viral life cycle: TRIM5a proteins, which inactivate incoming
viral capsids; cytidine deaminases (e.g., APOBEC3G), which
inhibit reverse transcription and introduce hypermutations into
the viral genome; SAM domain- and HD domain-containing
protein 1 (SAMHD1), which restricts HIV-1 infection of myeloid
cells; and tetherin (also known as CD317 or BST2), which
suppresses virion release from infected cells (reviewed in Malim
and Emerman, 2008; Kirchhoff, 2010; Laguette and Benkirane,
2012). These antiviral factors are under selection pressure
for diversification because they are engaged in an ‘‘arms race’’
with pathogenswhich themselves are adapting and evading theirCell Host & Mactivity (Meyerson and Sawyer, 2011). As a consequence, they
act in a species-specific manner and provide protection against
cross-species transmissions. However, these protective barriers
can fail, as exemplified by the AIDS pandemic. One reason for
this failure is that ‘‘modern’’ primate lentiviruses, i.e., SIV and
HIV-1, have evolved effective countermeasures against the
restriction factors of their respective hosts. These viral factors,
which include Vif, Vpr, Vpu, Vpx, and Nef, are not essential for
replication in some cell lines but required for efficient viral
replication and spread in vivo.
Recent studies provided surprising details into the zoonotic
origins of HIV-1 groups M, N, O, and P and the adaptive changes
that followed during their replication in humans. It is now estab-
lished that SIVcpz, the direct precursor of pandemic HIV-1,
represents a recombinant of precursors of viruses nowadays
found in red-capped mangabeys and Cercopithecus monkeys
(Bailes et al., 2003). This chimeric virus received a vpu gene
from the precursor of SIVgsn/mus/mon and a nef gene from
the progenitor of SIVrcm and was thus equipped with two poten-
tial tetherin antagonists (Sauter et al., 2009). During adaptation in
chimpanzees, Nef but not Vpu evolved to counteract tetherin.
Nef was maintained as the tetherin antagonist after transmission
of SIVcpz to gorillas, most likely because chimpanzee and gorilla
tetherins are highly similar. However, this was not the case after
zoonotic transmissions of SIVcpz and SIVgor to humans
because the human tetherin ortholog contains a deletion that
renders it resistant to Nef (Jia et al., 2009; Lim et al., 2010; Sauter
et al., 2009; Zhang et al., 2009). The precursor of pandemic HIV-1
group M cleared this hurdle by switching from Nef to Vpu to
counteract tetherin in the new human host (Sauter et al., 2009).
In contrast, the Vpu and Nef proteins of nonpandemic HIV-1
group O and P strains remained poor tetherin antagonists, and
group N Vpus gained some antitetherin activity but lost their
capacity to degrade CD4 (Sauter et al., 2009; Sauter et al.,
2011; Yang et al., 2011). Thus, tetherin poses a barrier for SIV
transmission from primates to humans and only HIV-1 group M
has fully cleared this hurdle.
Based on the above, it seems clear that switches between
Nef- and Vpu-mediated tetherin antagonism preceded the
emergence of pandemic HIV-1 and that the reacquisition oficrobe 12, 373–380, September 13, 2012 ª2012 Elsevier Inc. 373
Cell Host & Microbe
Evolution of Nef-Mediated Tetherin Antagonisma once lost Vpu function may have been a prerequisite for the
effective spread of the AIDS pandemic. Currently, it is unknown
how rapidly accessory primate lentiviral proteins can regain lost
activities against host restriction factors. To address this, we
examined how HIV-1 evolved to antagonize tetherin after
experimental infections of chimpanzees, which were conducted
over 10 years ago in the context of vaccine and pathogenesis
studies (Novembre et al., 1997; Mwaengo and Novembre,
1998). We found that two closely related molecular clones of
chimpanzee adapted HIV-1 regained Nef-mediated antitetherin
activity. This came as a surprise, as both viruses also maintained
their Vpu-mediated counteraction of tetherin. Most strikingly,
we could demonstrate that as few as two amino acid changes
were sufficient to render HIV-1 Nef active against chimpanzee
tetherin. Thus, after a century of replicating in humans, HIV-1
Nef reacquired antitetherin activity within a single passage in
its original host.
RESULTS
A Chimpanzee-Adapted HIV-1 Strain Utilizes Both Vpu
and Nef to Antagonize Tetherin
To examine how Vpu and Nef function evolved after reintroduc-
tion of HIV-1 into its original chimpanzee (CPZ) host, we took
advantage of two molecular clones (JC16 and NC7) derived
from chimpanzees that were experimentally infected with
HIV-1 in the mid 1980s (Novembre et al., 1997; Mwaengo and
Novembre, 1998). JC16 was derived from CPZ C499, which
was initially infected with the SF2 (also called ARV-2) isolate
of HIV-1 in 1985 and subsequently inoculated with a CPZ-
passaged LAV strain amplified in human peripheral blood mono-
nuclear cells (PBMCs) (Fultz et al., 1987) in 1986 (Figure 1A).
Notably, a molecular clone of SF2 contains a defective vpu
gene, suggesting that this HIV-1 strain may not encode a func-
tional tetherin antagonist. Cloning of JC16 was performed by
PCR amplification of proviral sequences from a coculture of
C499-derived PBMCs with cells from an uninfected CPZ
(Mwaengo and Novembre, 1998). JC16 was obtained about 10
years after infection when C499 had developed severe CD4+
T cell depletion and AIDS (Novembre et al., 1997). NC7 was
cloned from a second CPZ (C455) 1 month after transfusion
with blood from C499.
Phylogenetic analyses showed that JC16 represents a re-
combinant between the LAV and SF2 strains. Most parts of the
JC16 genome clustered with LAV, except for (1) the vpr gene,
(2) a short stretch of 228 nucleotides encoding portions of the
gp41 transmembrane, Tat and Rev proteins, and (3) most of
the nef gene and the LTR region (Figure 1B). We found that the
JC16 and NC7 Vpu amino acid sequences are identical (Fig-
ure 1C) and those of Nef differ only by a single substitution in
the N terminus (Figure 1D). However, the CPZ-adapted Vpu
and Nef sequences showed multiple differences from those of
molecular clones derived from the parental SF2 and LAV
isolates. Notably, the AxxxAxxxA motif that is conserved in
HIV-1 Vpus and is critical for counteraction of human (HU) teth-
erin (Vigan and Neil, 2010; Skasko et al., 2012) was mutated to
AxxxTxxxA (Figure 1C). The three A residues have been shown
to interact directly with the transmembrane region of tetherin
(Skasko et al., 2012). Thus, a V30M substitution in the CPZ374 Cell Host & Microbe 12, 373–380, September 13, 2012 ª2012 Eltetherin ortholog may have selected for the A15T adaptation in
Vpu. The JC16 Nef exhibited multiple changes compared to
the parental LAV and SF2 Nef proteins, but most of them clus-
tered near the N terminus and in the C loop of Nef known to be
critical for the interaction with adaptor protein (AP) complexes
(Figure 1D). Although the chimpanzee-derived HIV-1 Vpu and
Nef sequences varied substantially from those of the input
HIV-1 strains, most functional domains, such as the b-TrCP-
binding motif (DSGxxS) in Vpu and the acidic domain and the
P(xxP)3 and ExxxLL motifs in Nef, were conserved.
To determine how Vpu and Nef function evolved during
readaptation of HIV-1 to chimpanzees, we cotransfected 293T
cells with vectors coexpressing Vpu or Nef and eGFP together
with constructs expressing HU or CPZ derived CD4. Flow
cytometric analyses showed that the JC16 Vpu and Nef
proteins reduced HU and CPZ CD4 cell surface expression
by more than 80% and were thus fully active (Figures 2A and
2B). The JC16 Nef also downmodulated class I MHC and
(weakly) CD28 cell surface expression in PBMCs (Figures S1A
and S1B available online). Analyses of Vpu and Nef proteins
containing a C-terminal AU-1 tag confirmed these results and
showed that all constructs expressed proteins of the expected
size (Figure S1C).
To test whether the CPZ-adapted HIV-1 Vpu maintained its
capability to counteract tetherin, we first examined its effect on
the cell surface expression levels of HU and CPZ tetherin. The
JC16, LAV and NL4-3 Vpus reduced the levels of HU and CPZ
tetherin surface expression by about 40% to 50%, whereas
the SIVcpz GAB1 Vpu was inactive (Figures 2C and S1D). In
contrast, the JC16 and GAB1 Nefs efficiently reduced the
surface levels of CPZ but not of HU tetherin, whereas the LAV
and SF2 Nefs generally had only modest effects (Figures 2D
and S1D). Thus, the CPZ-adapted HIV-1 JC16 Nef showed
a functional phenotype similar to SIVcpz Nefs and distinct from
HIV-1 Nefs. Next, we measured infectious virus yields from
293T cells after cotransfection of a DVpuDNef HIV-1 NL4-3
proviral vector with fixed quantities of Vpu and Nef constructs
and different doses of tetherin expression plasmid. Our data
showed that the JC16 Vpu maintained the ability to antagonize
tetherin, being even slightly more effective against the CPZ
than against the HU ortholog (Figure 2E). As mentioned above,
this may be due to an A15T change in the TMD of the JC16
Vpu. While the antitetherin activity of the JC16 Vpu was as ex-
pected, it came as a surprise that the JC16 Nef also counter-
acted CPZ tetherin (Figures 2F and S1E).
Finally, we used proviral constructs to test the function of JC16
Nef and Vpu. The analysis of nef-defective JC16 constructs
with or without a functional vpu gene confirmed that this CPZ-
adapted HIV-1 strain uses both Vpu and Nef to antagonize
CPZ tetherin (Figure 2G). In contrast, the CPZ-adapted HIV-1
JC16 strain did not efficiently counteract HU tetherin. We also
examined whether the JC16 Nef targets the same residues as
Nefs from wild-type SIVcpz strains. In agreement with previous
studies (Jia et al., 2009; McNatt et al., 2009; Sauter et al.,
2009), introduction of five amino acids (D15IWKK19) that are
missing in the N-terminal part of HU tetherin restored its sensi-
tivity to the JC16 Nef (Figure 2H). Thus, CPZ passage restored
the capability of this HIV-1 Nef to target the region missing in
the HU tetherin ortholog.sevier Inc.
Figure 1. Origin and Properties of the CPZ-Adapted HIV-1 Clones JC16 and NC7
(A) Overview of the derivation of the CPZ-adapted HIV-1 JC16 and NC7 molecular clones. The numbers in parentheses give month and year of intravenous (i.v.)
infection. See the main text for details.
(B) Generation of the recombinant JC16 genome from LAV and SF2 parental viruses. Open reading frames are indicated as boxes with HXB2 coordinates
indicating inferred breakpoints (Korber et al., 1998). Neighbor-joining phylogenetic trees for the SF2 and LAV derived segments are shown above and below the
recombination scheme, respectively. Bootstrap supportR70% is shown above branches. Scale bars indicate genetic distance of 0.01.
(C and D) Alignment of Vpu (C) and Nef (D) amino acid sequences. The JC16 Vpu or Nef sequences are shown on top for comparison. The three Ala-residues
involved in tetherin interaction in the hydrophobic transmembrane (TM) domain, the two helical regions, and the b-TrCP-binding motif containing two phos-
phorylation sites are indicated in (C). The myristoylated N terminus, the acidic region and the P(xxP)3 motif, and the conserved core domain, the flexible C loop
region, and the C terminus in the JC16 Nef are indicated in (D). The colored bars indicate the regions used in the generation of chimeras between the JC16 and
LAV Nefs (see Figure 3A). Dashes indicate gaps introduced to optimize the alignment.
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Figure 2. Functional Activity of Vpu and Nef Proteins of a CPZ-Adapted HIV-1 Strain
(A–D) Levels of CD4 (A and B) and tetherin (C and D) cell surface expression in the presence of Vpu or Nef relative to levels measured in cells transfected with the
GFP control vector (100%). Values are averages (±SD) from three experiments. **p < 0.01, ***p < 0.001.
(E and F) Infectious virus yield from 293T cells cotransfected with the HIV-1 NL4-3 DVpuDNef construct and vectors expressing the indicated vpu (E) or nef (F)
alleles in combination with various quantities of plasmids expressing HU or CPZ tetherin.
(E–G) Panels give average values derived from triplicate infections of TZM-bl indicator cells relative to those obtained in the absence of tetherin expression vector
(100%). All results were verified by p24 ELISA.
(G) The JC16 clone uses both Nef and Vpu to antagonize tetherin. Virus release from 293T cells after transfection with 2.5 mg proviral JC16 WT construct or
mutants lacking nef (U+N–), vpu (U–N+), or both (U–N–) and varying amounts of plasmids expressing HU or CPZ tetherin.
(H) The JC16 Nef targets amino acid residues that aremissing in the human tetherin ortholog. 293T cells were transfectedwith plasmids expressing HU tetherin or
a variant in which the N-terminal deletion was restored (HU-INS). The middle panel shows the enhancement of infectious virus release relative to the eGFP only
control derived from triplicate infections of TZM-bl indicator cells. The right panel shows the reduction of the surface expression levels of the respective tetherin
variant in the presence of JC16 or GAB1 Nefs relative to those measured in cells transfected with the GFP only vector. Values are averages (±SD) from three
independent experiments. The deletion in HU tetherin is highlighted by a yellow box.
See also Figure S1.
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to a Current HIV-1 Nef
Tomap the determinants of antitetherin activity in Nef, we gener-
ated a set of recombinants between the active JC16 Nef and the
inactive LAV Nef (Figure 3A). Analysis of the recombinant Nefs
showed that downmodulation of tetherin and enhancement of
virion release was critically dependent on the presence of the
C-terminal flexible loop (C loop) of JC16 (Figure 3A). Next, we
swapped only the C loops of HIV-1 and SIVcpz Nefs (Figure 3B)
and found that the presence of the JC16 C-loop (LAV-JC C loop)
increased the antitetherin activity of LAV Nef, while insertion of
the LAV loop (JC-LAV C loop) reduced the functional activity of
JC16 Nef (Figure 3C). Further analyses demonstrated that the376 Cell Host & Microbe 12, 373–380, September 13, 2012 ª2012 Elcentral ten amino acids of the C loop (named Ccen) play a key
role in Nef-mediated anti-tetherin activity (Figures S2A and
S2B). Examination of single to triple amino acid substitutions
demonstrated that changes of the variable residues within the
otherwise conserved E/DxxxLL motif (DNI161-163NTS) as well
as changes of MC168/169VS (named MC/VS) and a single
C169S substitution downstream of this motif severely impaired
the capability of the JC16 Nef to counteract CPZ tetherin
(Figures 3D and S2C). Notably, none of these changes affected
other Nef activities, such as the downmodulation of CD4,
CD28, CD25,MHC-I, or CXCR4 (examples shown in Figure S2D).
We next examined the frequency of amino acid (aa) residues in
the E/DxxxLL motif and the four C-terminally adjacent residuessevier Inc.
Figure 3. Mapping Residues Critical for the
Gain of Antitetherin Activity by HIV-1 Nef
(A) The left panel indicates the chimeras between
the JC16 (yellow) and LAV (blue) Nefs analyzed.
Amino acid differences are indicated by vertical
dashes. The effect of various Nefs on expression
levels of CPZ tetherin (middle) or infectious virus
release in the presence of CPZ tetherin (right) are
shown as average values ± SD from triplicate
experiments.
(B) Alignment of HIV-1 and SIVcpz C-loop regions
of Nef. The JC16 C loop sequence is shown on top
for comparison. The E/DxxxLL motif and specific
mutants analyzed in (D) are indicated.
(C and D) Effect of Nefs differing in their C loop
sequences (C) or specific amino acids (D) on
infectious virus release in the presence of CPZ
tetherin. ‘‘LAV-JC C-loop’’ represents the LAV Nef
containing the C loop of the JC16 Nef and, vice
versa, ‘‘JC-LAV C-loop’’ represents the JC16
Nef containing the C loop of the LAV Nef. The
mutant JC16 Nefs contain changes of E158K,
DNS161-163NTS, MC169/169VS, and EAK174/
176/178DPR as shown in (B). Numbers give amino
acid positions in the JC16 Nef. Curves represent
the average infection values (n = 3) relative to
those obtained in the absence of tetherin.
See also Figure S2.
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conserved. However, SIVcpz Nefs usually contained an Ile (163I)
just next to the dileucine motif, whereas HIV-1 Nefs contained
a Ser or Cys residue at this position (Figure 4A). Furthermore,
an adjacent Cys (169C) residue was highly conserved in SIVcpz
Nefs, whereas HIV-1 M Nefs frequently encoded Ser or Asn.
Strikingly, these residues were not only critical for anti-tetherin
activity of the JC16 Nef, but the combination of the S163I and
S169C changes (SF2-IC) also rendered the HIV-1 SF2 Nef fully
active against CPZ tetherin (Figure 4B). Similarly, SF2 Nef
proteins containing 163C or 163V residues, which are present
in about 50% of all SIVcpz Nefs (Figure 4A), together with the
S169C substitution (SF2-CC, SF2-VC) also antagonized CPZ
tetherin (Figures S3A and S3B). None of these mutations in the
SF2 Nef had significant effect on the CD4 downmodulation func-
tion (Figure S3C). Examination of the localization of these resi-
dues in the SF2 Nef crystal structure, which includes the entire
C-terminal loop (Horenkamp et al., 2011), showed that despite
their close physical proximity the critical 163I and 169C residues
and the ExxxLL AP interaction site form distinct surfaces (Figures
4C and 4D). Moreover, the interaction site of Nef with CD4
(CAWL motif) is spatially well separated from the ExxxLL motif
(Figure 4C). Altogether, these results suggest that residues
163I and 169C are specifically involved in the interaction of Nef
with tetherin.
Aminority of HIV-1 nef alleles encode a cystein at position 169,
just like the vast majority of SIVcpz Nefs (Figure 4A). To examine
whether a subset of contemporary HIV-1 Nefs is active against
CPZ tetherin, we selected 12 previously described patient-
derived nef alleles (Specht et al., 2010) that encoded 169C either
together with 163S (as in most HIV-1 Nefs) or with 163C (as in
some SIVcpz Nefs) (Figure S3D). All these HIV-1 nef alleles
were substantially less potent in antagonizing CPZ tetherinCell Host & Mthan the CPZ-adapted JC16 Nef (Figure S3E). However, HIV-1
nef alleles encoding 163C/169C were somewhat more active in
promoting virus release in the presence of CPZ tetherin than
those encoding 163S/169C (Figure S3F). Thus, some contempo-
rary HIV-1 Nefs that contain the same residues as SIVcpz Nefs at
amino acid positions 163 and 169 exhibit a modest activity
against CPZ tetherin.
DISCUSSION
High mutation rates are a key feature of primate lentiviruses and
allow them to efficiently adapt to their respective host environ-
ments. One might expect that this high adaptability comes at
a cost in that viral genes which function in a species-specific
manner should rapidly accumulate disruptive mutations. Sur-
prisingly, however, we found that HIV-1 reacquired the ability
to use its Nef protein to counteract CPZ tetherin within a single
passage after reintroduction into its original chimpanzee host.
Moreover, just two amino acid changes (S163I and S169C) in
the C loop of HIV-1 Nef conferred full antitetherin activity (Fig-
ure 4). This is quite striking given that the chimpanzee-human
transmission event of SIVcpz that resulted in the emergence of
pandemic HIV-1 group M strains, which led to the disruption of
the Nef mediated antitetherin activity, is estimated to have
occurred a century ago (Korber et al., 2000; Worobey et al.,
2008).
To our current knowledge both Nef and Vpu lost and regained
antitetherin activity several times during the cross-species trans-
mission events that preceded the emergence of AIDS. Nef is well
known for its multifunctionality and most of its activities, such as
downmodulation of CD4 and MHC-I or enhancement of viral
infectivity, are species-independent (reviewed in Kirchhoff
et al., 2008). Similarly, Vpu not only antagonizes tetherin in aicrobe 12, 373–380, September 13, 2012 ª2012 Elsevier Inc. 377
Figure 4. Two Amino Acid Changes Confer
Antitetherin Activity to the HIV-1 SF2 Nef
(A) The upper panel gives frequency plots of amino
acid residues in and next to the ExxxLL motif of
HIV-1 M and SIVcpz Nef proteins, and the lower
panel shows the mutations in the SF2 Nef
analyzed in (B). The triangles indicate residues
critical for anti-tetherin activity.
(B) Infectious virus yield from 293T cells co-
transfected with the NL4-3 DVpuDNef con-
struct, vectors expressing the indicated nef
alleles, and various quantities of plasmid ex-
pressing CPZ tetherin. The SF2 Nef mutants
contain changes of NSS161/163/169DIC (SF2-
DIC), S169C (SF2-C), and SS163/169IC (SF2-
IC). All values represent averages of three
measurements and are shown relative to those
obtained in the absence of tetherin expression
vector (100%). Results were confirmed in two
independent experiments and by measuring p24
release.
(C) Structure of the HIV-1 Nef protein. The I163
and C169 (red) residues critical for tetherin
antagonism and the acidic residue and two
leucines (orange) in the E/DxxxLL motif involved in
the interaction with AP complexes and the CAWL
motif (yellow) involved in CD4 binding are indi-
cated.
(D) Localization of residues critical for tetherin
antagonism and AP interaction (all indicated by dots) and electrostatic surface potential of the C-terminal flexible loop of the SF2 Nef. Changes of S163I and
S169C that are critical for the antitetherin activity of Nef generate a hydrophobic groove in the otherwise largely polar C loop.
See also Figure S3.
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of the host species (Sauter et al., 2009). Thus, even when Nef
or Vpu lose a host-specific function after a cross-species
transmission event, the preservation of the remaining activities
will ensure the maintenance of genes that also remain predis-
posed to quickly regain the disrupted functions. It is thus
tempting to speculate that a common byproduct of the multi-
functionality of lentiviral accessory genes is an increased
potential of these viruses to overcome species barriers. In fact,
recent evidence suggests that Vpr and Vpx are also multifunc-
tional (Planelles and Barker, 2010) and that the accessory viral
proteins may generally interact with multiple cellular factors
(Ja¨ger et al., 2012).
Our finding that after reintroduction into its original chimpan-
zee host, HIV-1 not only evolved Nef-mediated activity against
CPZ tetherin, but also maintained Vpu as a tetherin antagonist,
adds to the evidence that tetherin antagonism is advantageous
for viral spread in vivo (Liberatore and Bieniasz, 2011; Serra-
Moreno et al., 2011). Perhaps more importantly, the present
data are derived from an animal model that represents the
closest approximation of AIDS in humans, i.e., infection of our
closest relative, the chimpanzee, with pandemic HIV-1 group M
strains. In comparison, previous in vivo results were obtained
either in mouse models that required IFN induction to demon-
strate definitive effects of tetherin or the SIVmac/macaquemodel
(Liberatore and Bieniasz, 2011; Serra-Moreno et al., 2011).
The finding that the CPZ-adapted HIV-1 strain maintained two
tetherin antagonists was unexpected since most primate lentivi-
ruses use Nef, Vpu, or Env to antagonize this restriction factor.
Chimpanzee C499 was productively infected with two different378 Cell Host & Microbe 12, 373–380, September 13, 2012 ª2012 ElHIV-1 isolates, i.e., ARV-2 (SF2) in 1985 and LAV in 1986. The
SF2 molecular clone, which is derived from ARV-2, encodes
a grossly truncated Vpu (Figure 1C). Thus, it is tempting to spec-
ulate that the SF2 strain initially evolved Nef as an antagonist of
CPZ tetherin because it lacks a functional Vpu. Later, LAV re-
combined with this virus, and the resulting CPZ-adapted JC16
strain received the critical region of the nef gene from SF2 (Fig-
ure 1B). Importantly, JC16 was particularly fit to replicate in
chimpanzees since C499 ultimately developed high viral loads
and AIDS. Furthermore, transfusion of its blood into a second
ape (C455) was associated with high plasma viral loads and a
rapid and sustained decline of CD4+ T cells (Novembre et al.,
1997). Similarly, virus derived from C455 (termed NC) was
pathogenic in two additional chimpanzees, whereas other
HIV-1-infected chimpanzees did not show signs of disease
progression (Novembre et al., 2001; O’Neil et al., 2000). Thus,
the CPZ-adapted HIV-1 JC and NC strains may be particularly
pathogenic in chimpanzees and it is tempting to speculate that
the evolution of two effective tetherin antagonists may contribute
to their virulence.
In summary, we show here that just two amino acid changes in
the C loop of Nef are sufficient to fully restore the activity of
a contemporary HIV-1 group M strain against the tetherin ortho-
log of its original chimpanzee host. Nef seems to be highly prone
to regain antitetherin activity because it uses similar domains
and mechanisms to down-modulate CD4 and to antagonize
tetherin. In comparison, the functional constraints on Vpu may
be less stringent because multiple changes in the TM region
of SIVcpz Vpus seem to be required to confer activity against
HU Tetherin (Lim et al., 2010). This may help to explain whysevier Inc.
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within a single ape passage, whereas HIV-1 group O and
P Vpus have thus far been unable to gain antitetherin activity in
humans (Sauter et al., 2009; Sauter et al., 2011; Yang et al.,
2011). It will be of interest to further elucidate whether viral
proteins that counteract antiviral factors in a species-specific
manner have also commonly evolved functions or interactions
that are species independent to avoid their complete inactivation
and elimination after cross-species transmission.
EXPERIMENTAL PROCEDURES
JC16 and NC7 Molecular Clones
Generation of the JC16 and NC7 infectious molecular clones was performed
as described previously (Mwaengo and Novembre, 1998). Splice overlap
extension PCR was used to generate vpu- and/or nef-defective mutants.
See the Supplemental Experimental Procedures for details.
Expression Vectors
Bicistronic CMV-based pCGCG expression vectors coexpressing vpu, nef,
CD4, or tetherin and eGFP or DsRed2 have been described previously (Sauter
et al., 2009). Splice overlap extension PCR with primers introducing XbaI and
MluI restriction sites flanking the reading frames was used to generate
chimeric nef alleles and nef mutants. PCR fragments were purified from
agarose gels and inserted into the pCGCG vector using standard cloning tech-
niques. All PCR-derived inserts were sequenced to confirm their accuracy.
Recombination Analysis of JC16
The recombination breakpoints of JC16 were determined as described in the
Supplemental Experimental Procedures.
Cell Culture and Transfections
Cells were cultured and transfected as described in the Supplemental Exper-
imental Procedures.
Flow Cytometric Analysis
To determine the effect of Vpu and Nef on CD4 and tetherin cell surface
expression, 293T cells were transfected by the calcium phosphate method
with 1 mg CD4 or tetherin expression vector coexpressing eGFP and 5 mg
pCGCG eGFP/Vpu or Nef constructs expressing eGFP alone or together
with Vpu or Nef. Two days after transfection, CD4 or tetherin expression
was examined by FACS analysis. See the Supplemental Experimental
Procedures for details.
Tetherin Antagonism
The capability of Vpu and Nef to antagonize tetherin was determined essen-
tially as described previously (Sauter et al., 2009). For details, see the Supple-
mental Experimental Procedures.
Western Blot
Expression of Vpu, Nef and tetherin was examined as described in the Supple-
mental Experimental Procedures.
Sequence Analyses
Vpu or Nef amino acid sequences were aligned using multiple sequence
alignment with hierarchical clustering (http://multalin.toulouse.inra.fr/). Vpu
and Nefs sequences were drawn from the HIV Sequence Database (http://
www.hiv.lanl.gov).
Nef Model Building
Mutations of S163C and S169I were inserted into the SF2 Nef structure as
specified in the Supplemental Experimental Procedures.
Statistical Analysis
All statistical calculations were performed with a two-tailed unpaired
Students t test using Graph Pad Prism Version 5.0. p values < 0.05 wereCell Host & Mconsidered significant. Correlations were calculated with the linear regression
module.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.chom.2012.07.008.
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